MedeliX
Start asking

maraviroc

Celsentri · ATC code J05AX09

Also known as: Maravirok

Key facts
Active substance
maraviroc
Drug class
Enisamium iodide
ATC code
J05AX09
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
CELSENTRI 150 mg film-coated tablets / CELSENTRI 300 mg film-coated tablets · CELSENTRI 20 mg/mL oral solution
Marketing authorisation holder
ViiV Healthcare B.V.
Information as of
2026-10-28

Key facts

Maraviroc (Celsentri) is a CCR5 co-receptor antagonist used with other antiretrovirals in treatment-experienced patients infected with only CCR5-tropic HIV-1.

What it is used for

  • Celsentri film-coated tablets: in combination with other antiretrovirals for treatment-experienced adults, adolescents and children weighing at least 30 kg infected with only CCR5-tropic HIV-1.
  • Celsentri 20 mg/mL oral solution: the same use in treatment-experienced patients from 2 years of age and weighing at least 10 kg.
  • Only CCR5-tropic virus must be confirmed with a validated test on a newly drawn blood sample before treatment.

Dosing

  • Adults (tablets or oral solution), depending on concomitant medicines: 150 mg twice daily with a potent CYP3A inhibitor (with or without an inducer), 300 mg twice daily without potent CYP3A inhibitors or inducers, 600 mg twice daily with a potent CYP3A inducer without an inhibitor.
  • Children and adolescents: dose based on body weight and concomitant medicines, not exceeding the adult dose; see the full text for the weight tables.
  • Adults with creatinine clearance <80 mL/min receiving potent CYP3A4 inhibitors: 150 mg once daily; caution in severe renal impairment (CLcr <30 mL/min).
  • Limited data in hepatic impairment; see the full text.

Contraindications

  • Celsentri film-coated tablets: hypersensitivity to the active substance, to peanut or soya, or to any of the excipients.
  • Celsentri oral solution: hypersensitivity to the active substance or to any of the excipients.

Important warnings

  • Hepatotoxicity and hepatic failure with allergic features have been reported; discontinuation should be strongly considered with signs of acute hepatitis, especially with suspected hypersensitivity.
  • Severe and potentially life-threatening skin and hypersensitivity reactions; stop immediately if they develop.
  • Symptomatic postural hypotension, particularly at higher doses, with blood-pressure-lowering medicines or in severe renal insufficiency.
  • Coronary heart disease events were more common with maraviroc than placebo in treatment-experienced patients; caution in severe cardiovascular disease.

Side effects

  • Common: nausea, diarrhoea, fatigue and headache (the most frequently reported reactions).
  • Serious: hepatotoxicity, severe skin and hypersensitivity reactions, postural hypotension.

Interactions

  • Metabolised by CYP3A4 and CYP3A5; CYP3A4 inducers decrease and inhibitors increase maraviroc levels, so the dose is adjusted.
  • Potent CYP3A4 inhibitors include ritonavir-boosted protease inhibitors (except tipranavir/ritonavir), cobicistat, itraconazole, voriconazole, clarithromycin and telithromycin.
  • St John's wort is not recommended (may reduce maraviroc levels and response).

Pregnancy and breastfeeding

  • Limited data in pregnant women; maraviroc should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • CelsentriViiV Healthcare B.V. · EMEA/H/C/000811

Source: European Medicines Agency (EMA), product information

Austria

  • MaravirocWaymade B.V. · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • MaravirocWaymade B.V., Amarox Pharma Gmbh · 3 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • CelsentriGLAXOSMİTHKLİNE İLAÇLARI SAN. VE TİC. A.Ş. · 8 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 8 more European countries
France
Maraviroc
Iceland
Celsentri
Italy
Maraviroc Waymade
Liechtenstein
Celsentri
Netherlands
Maraviroc
Norway
Celsentri
Portugal
Maraviroc
Spain
Maraviroc Tarbis, Maraviroc Waymade

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Celsentri – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/celsentri-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. Wikidata (CC0): ATC J05AX.

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.